SEC Form 4 · accession 0001209191-18-033088
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Antony A Riley
Officer — Chief Financial Officer
Period of report
Mar 8, 2018
Accepted (ET)
May 24, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 22, 2018 | P | 2,800 | $10.75 | A | 2,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.85 | Mar 8, 2018 | A | 25,000 | A | — | Mar 8, 2028 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The options were awarded on March 8, 2018 and vest ratably over a four-year period.